Engineered Protein Inhibitors of SARS-CoV-2 Entry: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
Shea Bailey (talk | contribs) No edit summary |
||
| Line 30: | Line 30: | ||
==Binding Site and Interactions== | ==Binding Site and Interactions== | ||
In order to best target the RBD of the spike protein, the minibinders reveal a wide range of interactions to compete with <scene name='10/1078124/Ace2/ | In order to best target the RBD of the spike protein, the minibinders reveal a wide range of interactions to compete with <scene name='10/1078124/Ace2/4'>ACE2 binding</scene>. | ||
The first design method, Rosetta, created AHB2 based on the single interacting helix of ACE2. With <scene name='10/1078124/Ahb2/1'>AHB2 binding</scene>, we see two alpha helices mimicking ACE2. Hydrogen bonding interactions between N36, D11, K43, E41, and E30 of the minibinder interact with residues K417, R403, Y449, Q493, and N487, respectively, in the spike protein. | The first design method, Rosetta, created AHB2 based on the single interacting helix of ACE2. With <scene name='10/1078124/Ahb2/1'>AHB2 binding</scene>, we see two alpha helices mimicking ACE2. Hydrogen bonding interactions between N36, D11, K43, E41, and E30 of the minibinder interact with residues K417, R403, Y449, Q493, and N487, respectively, in the spike protein. | ||
